Polyclonal anti-tumor necrosis factor-alpha Fab used as an ancillary treatment for severe malaria.

Journal article

Single doses (250, 500, 1,000, or 2,000 units/kg) of an ovine polyclonal-specific Fab fragment directed against tumor necrosis factor-alpha (TNF-alpha) were given to 17 adult patients with severe falciparum malaria immediately before treatment with artesunate in a pilot study to assess safety and optimal dosage with a view to future studies. Clinical and laboratory variables were compared with 11 controls. In the groups given Fab, there was a tendency for a faster resolution of clinical manif...

Expand abstract

Authors: Looareesuwan, S; Sjostrom, L; Krudsood, S; Wilairatana, P; Porter, R

• Publication status: Published
• Journal: American journal of tropical medicine and hygiene
• Volume: 61
• Issue: 1
• Pages: 26-33
• Publication date: 1999-07-01
• EISSN: 1476-1645
• ISSN: 0002-9637
• Language: English
• Keywords: Artemisinins; Interferon-gamma; Area Under Curve; Male; Sesquiterpenes; Aged; Tumor Necrosis Factor-alpha; Interleukin-6; Adult; Parasitemia; Immunoglobulin Fab Fragments; Malaria, Falciparum; Mefloquine; Middle Aged; Kinetics; Immunoassay; Animals; Adolescent; Intercellular Adhesion Molecule-1; Pilot Projects; Female; Humans; Interleukin-8; Antimalarials; Interleukin-2; Interleukin-1; Plasmodium falciparum